Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.9016 USD -0.16% Intraday chart for Kezar Life Sciences, Inc. -6.57% -4.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from NASDAQ Biotechnology Index CI
Wells Fargo Adjusts Price Target on Kezar Life Sciences to $2 From $4, Maintains Equal-Weight Rating MT
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Investors Await -2- DJ
JonesTrading Downgrades Kezar Life Sciences to Hold From Buy MT
Kezar Life Sciences Launches Restructuring Program, Cuts Workforce, Names New CEO MT
Kezar Life Sciences, Inc. Announces Executive Changes CI
Kezar Life Sciences, Inc. Announces CEO Changes CI
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway CI
HC Wainwright Raises Kezar Life Sciences Price Target to $20 From $18, Maintains Buy Rating MT
Sector Update: Health Care Stocks Tick Lower Thursday Morning MT
North American Morning Briefing : The Post-Fed Selloff Continues DJ
Kezar Life Sciences Signs License Agreement With Everest Medicines to Develop, Market Zetomipzomib in Asia MT
Everest Medicines Signs License Deal with Kezar for Anti-Autoimmune Disease Medication MT
Stocks to Watch : FedEx, Kezar Life Sciences, Transcat DJ
Everest Medicines Enters into Collaboration and License Agreement with Kear Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and Other Asian Markets CI
Transcript : Kezar Life Sciences, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 10:50 AM
North American Morning Briefing : Stock Futures -2- DJ
Wells Fargo Downgrades Kezar Life Sciences to Equalweight From Overweight MT
HC Wainwright Adjusts Price Target on Kezar Life Sciences to $18 From $19, Maintains Buy Rating MT
Kezar Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from S&P Biotechnology Select Industry Index CI
HC Wainwright Adjusts Price Target on Kezar Life Sciences to $19 From $21, Keeps Buy Rating MT
Chart Kezar Life Sciences, Inc.
More charts
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.903 USD
Average target price
11.67 USD
Spread / Average Target
+1,191.99%
Consensus